For this Expert Insight, RiverVest spoke with Vikram Sudarsan, PhD, founder and CEO of Engrail Therapeutics about the significant unmet need for safer, more effective treatments for anxiety disorders and how the company's lead drug candidate, ENX-102, is addressing that need....
July 2023RiverVest's Niall O'Donnell Discusses State of Biotech VC in 2023 RiverVest Managing Director Niall O'Donnell, Ph.D.ST. LOUIS, MO (July 21, 2023) – From the St. Louis Business Journal, Beyond the List: St. Louis area's largest venture capital firms report managing $9B in capital.“Our newest List...
In this article, Managing Director Tom Melzer breaks down RiverVest's investment strategy, which centers on managing risk and capital efficiency with one goal in mind: a successful and profitable exit that will maximize investor return. ...
March 2023RiverVest Mourns Passing of William A. Peck, MD,RiverVest Scientific Advisory Board Founding Member /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} William A. Peck, MDSeptember 28, 1933 - February 22, 2023In MemoriamWe mourn the passing of William A. Peck, MD, who as the...
RiverVest co-founded and seed funded Lumena and built a clinical strategy to fast-track its lead drug compound through clinical trials....